<div id="readability-page-1"><p>Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) shares saw strong trading volume on Wednesday . 339,252 shares were traded  during trading, an increase of 96% from the previous session's volume of 172,719 shares.The stock last traded at $28.65 and had previously closed at $28.22.</p><h2>Wall Street Analyst Weigh In</h2><p>PHVS has been the topic of a number of recent research reports. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Pharvaris in a research report on Tuesday, April 21st. HC Wainwright  reiterated a &#34;buy&#34; rating and set a $60.00 price objective on shares of Pharvaris in a research note on Tuesday, March 3rd. Royal Bank Of Canada cut their target price on shares of Pharvaris from $52.00 to $51.00 and set an &#34;outperform&#34; rating on the stock in a report on Monday, April 6th. Citigroup  restated a &#34;buy&#34; rating on shares of Pharvaris in a research note on Wednesday, April 15th. Finally, Wedbush upped their target price on Pharvaris from $41.00 to $42.00 and gave the company an &#34;outperform&#34; rating in a report on Tuesday, April 7th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned  a Hold rating and one  has issued  a Sell rating to the company. According to data from MarketBeat.com, Pharvaris presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $42.73.</p><p><b>Check Out Our Latest Research Report on PHVS</b></p><h2>Pharvaris Price Performance</h2><p>The firm's fifty day moving average price is $27.51 and its 200-day moving average price is $25.97. The company has a market cap of $1.96 billion, a price-to-earnings ratio of -8.88 and a beta of -2.58. </p><p>Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.15).  As a group, equities analysts forecast that  Pharvaris N.V. will post -3.19 earnings per share for the current fiscal year. </p><h2>Insiders Place Their Bets</h2><p>In related news, CEO Berndt Modig sold 2,292 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $28.60, for a total value of $65,551.20. Following the completion of the transaction, the chief executive officer directly owned 139,792 shares of the company's stock, valued at $3,998,051.20. This represents a 1.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Peng Lu sold 7,001 shares of the firm's stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $30.05, for a total value of $210,380.05. Following the completion of the sale, the insider owned 66,083 shares in the company, valued at approximately $1,985,794.15. This represents a 9.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 54,426 shares of company stock worth $1,578,273. </p><h2>Institutional Trading of Pharvaris</h2><p>Large investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new stake in  Pharvaris in the 4th quarter valued at approximately $35,000.  JPMorgan Chase &amp; Co. increased its position in  Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase &amp; Co. now owns 3,342 shares of the company's stock valued at $59,000 after acquiring an additional 783 shares during the period.  China Universal Asset Management Co. Ltd. acquired a new stake in  Pharvaris in the 3rd quarter valued at approximately $75,000.  Barclays PLC acquired a new stake in  Pharvaris in the 4th quarter valued at approximately $77,000.  Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in  Pharvaris in the 4th quarter valued at approximately $86,000. </p><h2>Pharvaris Company Profile</h2> (Get Free Report)<p>Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.  </p><p>The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.</p><h2>See Also</h2><ul><li>Five stocks we like better than Pharvaris</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Pharvaris Right Now?</h2><p>Before you consider Pharvaris, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.</p><p>While Pharvaris currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PHVS

LABU

SBIO

<p>Pharvaris (NASDAQ:PHVS) experienced a significant increase in trading volume, with 339,252 shares traded, up 96% from the previous session. The stock price rose to $28.65 from $28.22. Analysts have mixed ratings, with Weiss Ratings issuing a 'sell' and HC Wainwright a 'buy' with a $60 target. The company reported a quarterly loss of $0.84 per share, missing estimates. Insiders have sold shares recently, and institutional investors are adjusting their stakes. Pharvaris focuses on developing therapies for rare diseases, particularly hereditary angioedema.</p>

Pharvaris (NASDAQ:PHVS) Sees Large Volume Increase - What's Next?